Arthrofibrosis Musculoskeletal Diseases
Conditions
Interventions
Registered patients were randomized to either VC at a daily dose of 1000 mg (two 500 mg tablets) or to matching placebo starting on the preoperative day and continuing for a total of 50 days. Randomiz
Sponsors
Cantonal Hospital St Gallen
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with primary osteoarthritis of knee joint undergoing TKA presenting with grade 3 or 4 osteoarthritis (Kellgren-Lawrence score) 2. Age =18 years 3. Written informed consent, including written consent to participate in the local prosthesis registry of the hospital
Exclusion criteria
Exclusion criteria: 1. History of nephrolitiasis, hematochromatosis, uremia, beta-thalassemia 2. Known intolerance to vitamin C or any of the excipients 3. Dietary vitamin C intake 10mg/l
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Knee joint ROM measured with a goniometer by a trained study nurse who was blinded to the research history, assessed preoperatively, at 8 weeks and 12 months postoperatively | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Incidence of arthrofibrosis (AF), defined as extension deficit >5° and/or = 100° flexion of the knee, measured at 8 weeks and 12 months postoperatively 2. Vitamin C plasma concentrations measured in µmol/l before surgery and 4 and 7 days after surgery 3. The Western Ontario and McMaster Universities Arthritis Index (WOMAC) measured at 8 weeks and 12 months postoperatively 4. The Forgotten Joint Score-12 (FJS-12) measured at 8 weeks and 12 months postoperatively | — |
Countries
Switzerland
Contacts
Public ContactHenrik Behrend
Outcome results
None listed